Jill Feldman, Co-Founder of EGFR Resisters, shared a post on X:
“We must talk about pneumonitis in lung cancer treatment!
Resistance is horrible, but you understand the reasoning behind stopping treatment. When a treatment is working and has to be stopped due to pneumonitis, it sidelines patients & eliminates many future options – It is cruel and DEVASTATING!
This needs more attention, more research, and urgency to:
- Understand who’s at risk?
- Improve how it is managed.
- Identify treatment options.”
Eric K. Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, reshared the post on X, adding:
“GREAT points as always, Jill Feldman.
Immunotherapy, targeted therapy, ADCs and radiation can all potentially lead to pneumonitis—and many promising trials exclude patients with a history of it.”